There's a line item in your health plan quietly costing you a fortune, and you've never even noticed it.
Food allergies cost the U.S. about $25 billion a year. A 2013 JAMA Pediatrics study put the figure at $24.8 billion annually, most of it borne by families through medical costs, special diets, and lost productivity. Employer plans absorb a growing portion through testing and treatment, and much of that spending goes to panels that leading immunology societies say should not be done at all.
While benefits leaders obsess over diabetes programs and cardiac screenings, this epidemic of unnecessary testing flies under the radar. It doesn't show up in your wellness dashboards. Your broker probably hasn't mentioned it. And your TPA's utilization reports? They're hiding the real story in aggregate lab spend numbers that look totally normal.
But once you understand what's happening here, you'll see that food allergy testing isn't just a cost problem. It's a window into everything broken about how we pay for healthcare, and a roadmap for fixing it.
How COVID Broke the Allergy Testing System
Something weird happened during the pandemic. People became obsessed with their immune systems, and that obsession didn't go away when the lockdowns ended.
Private insurance claim lines for food-induced anaphylaxis rose 377% from 2007 to 2016, according to FAIR Health data commissioned by FARE. Testing has expanded alongside that growth, and direct-to-consumer labs have pushed it further. The underlying prevalence of convincing food allergy among U.S. adults is about 10.8%, according to a 2019 JAMA Network Open survey of more than 40,000 adults.
So what changed? Several factors converged at exactly the wrong time:
- Telehealth exploded, removing traditional gatekeeping. Suddenly it was easy to order broad allergy panels without seeing a specialist.
- Wellness culture went mainstream. Elimination diets became biohacking and optimization instead of medical treatment requiring supervision.
- Direct-to-consumer lab companies figured out how to market directly to anxious employees through Instagram ads and wellness influencers.
The result: your organization is likely paying hundreds to thousands of dollars per affected employee for tests that major medical societies explicitly recommend against in most cases.
Allergy Testing Methods: Which One Is Worth Your Money?
Here is what happens when someone gets tested for food allergies. There are three main approaches, and the differences matter.
Skin Prick Testing: The First-Line Standard
This is the test you probably picture when you think about allergy testing. A trained professional places tiny amounts of allergen extracts on the skin and watches for reactions. It has high sensitivity, meaning a negative result reliably rules out a true immediate allergy. Positive results are less specific: a positive skin test can reflect mere sensitization rather than a real allergy, so results need interpretation in light of symptoms.
Cost-wise, a panel runs a few hundred dollars, often less than blood-based panels. Not cheap, but reasonable for a first-line test with real clinical value.
The problem is the opposite of what most benefits leaders expect: skin testing is underused where it matters. Employees with real allergies often don't get tested until they land in the emergency department with an anaphylaxis episode. That is a utilization problem, not a waste problem.
Blood IgE Testing: Where Things Start Going Sideways
This is a blood test that measures IgE antibodies to specific foods. When used appropriately, such as when skin testing is not feasible or when a few specific foods are tested based on clinical history, it is a legitimate diagnostic tool. Like skin testing, it is better at ruling allergies out than ruling them in.
Each allergen costs a modest amount, so testing three or four suspicious foods based on actual symptoms is reasonable and cheap.
The billing games start with bundling. Labs bundle 50 or more allergens into a single order. A patient comes in with a shellfish reaction and walks out having been tested for tree nuts, grains, vegetables, and foods they have eaten safely for decades.
A test that should cost a modest amount suddenly becomes a four-figure claim. And because it falls under lab services at most carriers, it sails through without prior authorization.
IgG Testing: No Clinical Validity
Now to the expensive problem. IgG food sensitivity testing is sold at a wide range of prices depending on how many foods are included, often several hundred dollars per panel.
And it has no clinical validity for diagnosing food allergies or intolerances.
The American Academy of Allergy, Asthma & Immunology, the American College of Allergy, Asthma and Immunology, and the European Academy of Allergy and Clinical Immunology have all published position statements saying IgG testing should not be used to diagnose food allergies.
Why? Because IgG antibodies don't indicate allergy. They indicate exposure. If you eat a food regularly, you'll have IgG antibodies to it. That's normal immune system function, not pathology.
Testing positive for IgG antibodies to wheat means you have eaten bread. It doesn't mean you're allergic to it, sensitive to it, or should avoid it.
Yet these panels have reached a wide audience. Many of the tests are paid out-of-network at inflated rates, and some are even covered as preventive care under poorly written plan documents.
That's real money paying for a test with no diagnostic value.
Four Ways Your Benefits Administration Is Failing
Problem #1: Medical Policies Without Medical Necessity
Across carrier and TPA medical policy documents, the pattern is consistent: many lack actual, evidence-based criteria for when food allergy testing is appropriate.
Most policies list the CPT codes as covered diagnostic services and call it a day. No requirements for documented clinical history. No distinction between IgE and IgG testing. No limits on panel size based on symptoms.
It's like having an imaging policy that says CT scans are covered without specifying when they're medically necessary. You wouldn't do that for radiology. Why are you doing it for immunology?
The fix: Adopt the American Academy of Allergy, Asthma & Immunology's appropriate use criteria as binding policy. Require documented clinical history. Limit initial panels to 10 or fewer foods based on patient symptoms. Require allergist consultation before approving larger panels. And categorically exclude IgG testing as not medically necessary.
Problem #2: Prior Authorization That Misses the Target
The pattern is common. An employee complains of bloating after meals. A primary care provider orders a large IgG panel from a direct-to-consumer lab. The claim arrives with no prior authorization requirement, and the plan pays it.
The employee then eliminates a long list of foods based on the results and develops nutritional deficiencies. Eventually a gastroenterologist orders an inexpensive lactose breath test and diagnoses lactose intolerance, something a targeted history and a cheap test could have identified on day one.
The cascade of nutrition counseling, follow-up testing, and treatment costs far more than the original panel.
Why did prior authorization fail? Most PA programs focus on high-cost imaging and procedures. Lab services typically fly under the radar, and lab companies structure their pricing to stay below typical PA thresholds while maximizing the number of tests they run.
The fix: Lower your PA thresholds specifically for multi-allergen panels, but streamline approval for targeted testing of 5 or fewer allergens with documented clinical history. This flips the incentive structure on its head.
Problem #3: Wellness Programs That Miss the Opportunity
Most wellness platforms track biometrics and send reminders for preventive screenings. Few flag inappropriate allergy testing patterns, offer pre-test education, or suggest allergist consultation before a panel is ordered.
Food allergy testing is an ideal target for wellness intervention because:
- Employees are highly motivated: they want answers about their symptoms
- Clear clinical guidelines exist
- The cost impact is real and measurable
- Education demonstrably prevents inappropriate utilization
A wellness platform could detect when an employee searches for 'food allergy test' or schedules an immunology appointment, then trigger an educational module explaining the difference between allergies and sensitivities, what to expect from testing, questions to ask a doctor, and red flags for tests that waste money.
Early employer programs using this approach report meaningful reductions in inappropriate testing and downstream costs.
Problem #4: The Out-of-Network Lab Loophole
The most expensive testing doesn't come through your network. It comes from direct-to-consumer labs that employees find on social media.
These companies have perfected a business model that exploits your plan design:
- They charge far above network or Medicare rates
- They bundle maximum allergens to maximize revenue per test
- They market directly to employees through wellness influencers
- They provide wellness consultations rather than medical diagnoses to avoid medical necessity requirements
- They process claims as out-of-network lab services, often paid at billed charges
The mechanics are simple. An employee orders a mail-in panel, pays out of pocket, then submits the claim for out-of-network reimbursement.
The plan pays its share, funding a test with no diagnostic value.
The fix: Amend your plan documents to explicitly exclude food allergy testing from out-of-network benefits unless it's pre-authorized by your medical director, performed by a board-certified allergist, and meets evidence-based medical necessity criteria.
The Hidden Costs Nobody Tracks
The direct cost of inappropriate testing is bad enough. But the cascade that follows has three phases, each adding to the bill.
Managing False Positives
- Unnecessary elimination diets
- Nutrition counseling sessions
- Specialty food costs (often reimbursed through FSA/HSA)
- Follow-up testing to confirm the misleading results
Nutritional Complications
- Vitamin and mineral deficiencies from overly restrictive diets
- Protein malnutrition
- Development of eating disorders, especially in younger employees
- Gastrointestinal symptoms caused by the dietary restrictions themselves
Delayed Correct Diagnosis
- Symptoms persist, leading to escalating workup
- GI procedures, imaging, multiple specialist consultations
- Eventually the correct diagnosis, usually GERD, IBS, or lactose intolerance
- Months of unnecessary anxiety and lost productivity
Add it up: an employee who gets an inappropriate panel can cost the plan thousands of dollars in downstream spending over the following two years. None of that shows up in your reports as allergy testing.
Across a 1,000-employee company, the preventable total is substantial.
Compliance Risks You Can't Ignore
ERISA Fiduciary Duty
Plan fiduciaries have a legal obligation to ensure plan assets are used exclusively for participant benefits and to pay only reasonable amounts for services. Paying for tests that clinical societies deem inappropriate arguably violates this duty.
And there is litigation risk. Participants harmed by false-positive results, whether through eating disorders, nutritional deficiencies, or delayed diagnosis, could argue the plan breached its duty by covering non-evidence-based testing without safeguards.
Document that your coverage policies align with recognized clinical guidelines. Make sure you have appropriate utilization management in place.
ACA Preventive Care Confusion
Some plans have mistakenly classified broad allergy panels as preventive care to avoid cost-sharing. This is wrong and potentially dangerous.
The ACA requires coverage of USPSTF Grade A and B preventive services without cost-sharing. The USPSTF has never recommended routine food allergy screening. Symptom-driven diagnostic testing is not preventive screening.
Regulators have shown growing scrutiny of inappropriate preventive service designations. Misclassifying diagnostic allergy testing could trigger compliance issues and financial penalties.
Mental Health Consequences
There is also an overlooked human cost: eating disorders triggered by inappropriate food allergy testing are a mental health consequence of poor physical health management.
A plan that pays freely for unproven panels while restricting access to eating disorder treatment invites scrutiny of that gap, and parity rules require a close look at any mismatch between how mental health and physical health benefits are managed.
How Prevention-First Economics Solves This
Traditional fee-for-service models create perverse incentives at every level:
- The lab gets paid more for larger panels
- The physician avoids conflict by ordering tests just to be sure
- The patient feels heard and validated
- The carrier pays the claim according to plan design
- The employer sees the cost buried in aggregate data months later
- Nobody is accountable for appropriateness
The WellthCare model flips this entirely by making appropriateness the primary organizing principle.
Before any testing happens, the employee's symptom search triggers an educational module. The goal is information, not gatekeeping. A virtual allergist consultation is available at zero copay and gets used first. The specialist determines the clinically appropriate testing pathway based on actual history and symptoms.
If testing is indicated, the employee proceeds and earns reward dollars at the WellthCare Store for completing the appropriate workup. If testing is not indicated, the employee still earns reward dollars for following the evidence-based pathway. Avoiding unnecessary testing becomes rewarded behavior, not a barrier to care. WellthCare, the Health-to-Wealth Benefit System, is purpose-built to eliminate these perverse incentives by rewarding appropriate utilization with earned store dollars and automatic retirement contributions, all within a compliance-grade platform that works alongside your existing health plan without disruption.
The economics realign completely:
- Employees win with zero copay expert consultation, Store dollars they can spend on health-related purchases, and actual answers to their health questions
- Employers win with a sharp reduction in inappropriate testing costs
- WellthCare wins with lower claims, healthier populations, and behavioral data proving preventive engagement
- Allergists win by getting paid fairly for cognitive work rather than just procedures
Allergist-first pathways reduce total allergy-related spend while increasing appropriate testing. Real allergies get caught earlier, before they become emergencies. Unnecessary panels never waste money in the first place.
Your Action Plan
Next 30 Days: Pull Your Data
Start by understanding your current state:
- Pull all food allergy testing claims (CPT codes 86003, 86005, 95004, 95024-95028)
- Calculate average allergens tested per panel
- Identify out-of-network lab utilization patterns
- Look for IgG testing, billed under CPT 86001 (allergen-specific IgG) or sometimes 83516
- Audit your medical policies for evidence-based criteria
- Review plan documents for inappropriate preventive classifications
Next 90 Days: Close the Gaps
- Implement evidence-based medical policies aligned with AAAAI guidelines
- Add prior authorization for panels exceeding 10 allergens
- Explicitly exclude IgG testing as investigational and not medically necessary
- Restrict out-of-network coverage for allergy testing
- Add pre-testing education modules to your wellness platform
Next 12 Months: Build the Infrastructure
- Integrate allergist consultation into your virtual primary care benefits as first-line access
- Launch member education campaigns about testing appropriateness
- Start tracking cascade costs across nutrition, GI, and mental health
- Consider centers of excellence partnerships for complex immunology cases
- Negotiate lab contracts with appropriate-use incentives built in
Regulatory Pressure on Direct-to-Consumer Labs
The market for the worst offenders is already shifting. In 2024, the FDA finalized a rule that phases out its long-standing enforcement discretion for laboratory-developed tests, bringing most of them under medical device regulation over a four-year window. Many direct-to-consumer IgG and food sensitivity panels are laboratory-developed tests. As the phase-in proceeds, plan sponsors should expect more scrutiny of these products' claims and more transparency about what these panels measure. That is a tailwind for evidence-based policy, but it does not fix your plan documents today. Your coverage and prior authorization rules remain the first line of defense.
The Bigger Picture
Food allergy testing is a microcosm of everything broken in preventive care economics. Demand driven by anxiety rather than evidence. Supply unconstrained by appropriateness criteria. Downstream harms invisible to utilization management. Perverse incentives at every level. Wellness programs disconnected from clinical reality.
The exact same dynamics exist in genetic cancer screening panels, microbiome testing, heavy metal toxicity panels, comprehensive hormone testing, tick-borne disease panels, and mold exposure testing. Each category carries the same structural problems.
Which means food allergy testing is not just about food allergies. It is a litmus test for your entire benefits strategy.
Plans with appropriate allergy testing management typically demonstrate strong medical management overall, evidence-based policy development, integrated wellness and clinical programs, data-driven decision making, and proactive cost management.
Plans with unmanaged allergy testing typically show weak utilization management broadly, policy gaps across diagnostic categories, disconnected wellness initiatives, and reactive cost management through blunt instruments like higher deductibles.
The more useful question is what your allergy testing utilization reveals about your entire approach to benefits.
The Choice You're Actually Making
The familiar choice between coverage and cost control is a false one, and it keeps employers trapped in the same broken system.
The choice that matters is between aligned systems that build health and wealth together and fragmented programs that accomplish neither.
Traditional plans can't achieve true alignment because their incentives are misaligned at every level. The Health-to-Wealth model fixes this by making prevention easier and more rewarding than waste, putting expert guidance before testing rather than after, turning appropriate utilization into tangible employee rewards, creating transparency where complexity used to hide excess, and building long-term wealth for employees who build long-term health.
Food allergy testing is the canary in the coal mine. Fix this one category, and you have built the infrastructure to fix everything else. Ignore it, and watch the waste compound while your employees get sicker, poorer, and more confused about what their benefits actually do.
That's the difference between healthcare that takes from you and healthcare that pays you back.
This article is for general information only and is not legal, tax, or medical advice. Employers should consult their own advisors.